Biological membrane transporters: Delivery of an oligonucleotide inhibitor of vascular endothelial growth factor (VEGF)

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/311216

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Choroidal neovascularisation, which is the most severe form of Age Related Macular Degeneration, is the major cause of blindness in the developed world. Gene therapy could be a cure for this disease if the problems associated with the delivery of DNA could be addressed. Our project involves a highly novel strategy for gene delivery involving ion pair formation of lipophilic dendrimers (tree-like compounds with positive charges on the surface). We will develop new DNA-dendrimer complexes and test them in a well established animal model for neovascularisation. Successful completion of this project might offer a potential therapy for choroidal neovascularisation, with a good chance of entering into human clinical trials.

Funded Activity Details

Start Date: 01-01-2004

End Date: 01-01-2005

Funding Scheme: NHMRC Development Grants

Funding Amount: $99,750.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Pharmacology and Pharmaceutical Sciences

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Charged dendritic systems | Drug Delivery | Drug Design | Lipophilic dendrimers | Oligonucleotide delivery

Related Links